Blog

Home  /  Covid-19   /  PTRCR15 – Remdesivir for the treatment of COVID-19. PICO and Evidence gaps – Final Rapid Collaborative Review now available

PTRCR15 – Remdesivir for the treatment of COVID-19. PICO and Evidence gaps – Final Rapid Collaborative Review now available

This is the first pharmaceutical Rapid Collaborative Review (PTRCR15) for – Remdesivir for the treatment of COVID-19. PICO and Evidence gaps.

In June, 2020, the European Commission granted marketing authorisation for Veklury® (remdesivir) for the treatment of Covid-19. This Rapid Collaborative Review aims to define, according to the national requirements of the EUnetHTA partners, the PICO and Evidence gaps of remdesivir in the target patient populations with relevant comparators.

For any questions regarding the Rapid Collaborative Review, please contact eunethta@zinl.nl.

Please find the review here:

PTRCR15 – Final Rapid Collaborative Review​